Abstract
The use of cytokines alone or in combination with other cytokines or cytotoxic drugs has had a profound effect upon widely metastatic disease in many cases. However, despite the encouraging results in early trials, there is much room for improvement. Few responses to these combinations are complete, and toxicity has in some cases been quite severe. Changes in dose, route, or schedule of administration of the drugs, or the development of cytokine analogs may lead to more efficacious and less toxic regimens. In addition, new cytokines such as interleukin (IL)-7 and IL-12 are currently under investigation for potential use in future immunotherapy trials. These prospects and the use of cytokine combinations are promising advances in the treatment of human cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abbruzzese JL, Levin B, Ajani JA (1989) Phase I trial of recombinant human ψ-IFN and recombinant human TNF in patients with advanced gastrointestinal cancer. Cancer Res 49: 4057
Arinaga S, Karimine N, Takamuku K, Nanbura S, Inoue H, Abe R (1992) Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low dose recombinant IL-2 and mitomycin C. Cancer Immunol Immunother 35: 246
Budd GT, Osgood B, Barnes B, Botett JM, Finke J, Medendorp SV (1989) Phase I clinical trial of IL-2 and α-IFN:, toxicity and immunologic effects. Cancer Res 49: 6432
Bukowski RM, Sergi JS, Budd GT, Murthy S, Tubbs R, Gibson V (1991) Phase I trial of continuous infusion IL-2 and doxorubicin in patients with refractory malignancies. J Immunother 10: 432
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin induced serum factor which causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666
Creagan E, Loprinzi CL, Ahmann DL (1988) A phase I/II trial of the combination of recombinant leukocyte A IFN and recombinant human IFN-γ in patients with metastatic malignant melanoma. Cancer 62: 2472
Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB (1991) IL-2 and high dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9: 1821
Demetri G, Spriggs D, Herman M (1989) A phase I trial of recombinant human TNF and IFN-γ effects of combination cytokine administration in vivo. J Clin Oncol 7: 1545
DeMulder PH, Debruyne FMJ, von Oosterom A (1991) EORTC randomized phase II study of recombinant IFN-α and recombinant α and γ in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 10: 166
Dewit R, Boucher CAB, Veenhof KHN (1988) Clinical and virological effects of high dose recombinant IFN-α in disseminated AIDS-related Kaposi's sarcoma. Lancet 2: 1214
Eriksson B, Oberg K, Alm G (1987) Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Cancer Treat Res 71: 31
Foon K, Doroshow J, Bonueur E (1988) A prospective randomized trial of α-2B IFN/γ-IFN or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 7: 540
Fossa S, Cavalli F, Otto U (1988) Randomized study of roferon-A with or without vinblastine in advanced or metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 7: 118
Garbe C, Kreuser E-D, Zouboulis CC, Stadler R, Orfanos CE (1992) Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 19: 63
Gately MK, Wolitzky AG, Quim PM, Chizzonite R (1992) Regulation of human cytolytic lymphocyte responses by IL-12. Cell Immunol 143: 127
Grimm EA, Mazumber A, Zhang HZ, Rosenberg SA (1982) The lymphokine-activated killer cell phenomenon: lysis of resistant and fresh solid tumor cells by IL-2 activated autologous human peripherai blood lymphocytes. J Exp Med 155: 1823
Hamblin T, Davies B, Saddulah S (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, IL-2, and α-IFN. Proc Am Soc Clin Oncol 10: 294
Heaton KM, Ju G., Morris DK, Delisio K, Bailon P, Grimm EA (1993) Characterization of lymphokine activated killing by human peripheral blood mononuclear cells stimulated with IL-2 analogs specific for the intermediate affinity IL-2 receptor Cell Immunol (in press)
Higuchi CM, Thompson JA, Lindgren CG, Gillis S, Widner MB, Fefer A (1989) Induction by interleukin 4 of lymphokine-activated killer activity in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res 49: 6487
Huland E, Huland H (1989) Local continuous high dose IL-2: a new therapeutic model for the treatment of advanced bladder cancer. Cancer Res 49: 5469
Jakubowski A, Larchian W, Starnes F (1988) Phase I trial of intravenous TNF plus IFN-γ in patients with advanced cancer. Proc Am Soc Clin Oncol 7: 164
Katre NV, Knauf MJ, Laird WJ (1987) Chemical modification of recombinant IL-2 by polyethylene glycol increases in potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA 84: 1487
Keslitz JE, Wong GY, Welte K (1988) Phase I trial of recombinant IL-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long term administration of recombinant IL-2. J Biol Response Mod 7: 457
Khayat D, Borel C, Antoine E (1992) Highly active chemoimmunotherapy (cisplatin, IL-2, α-IFN) in the treatment of metastatic malignant melanoma. Proc Am Soc Clin Oncol 11: 353
Kirchner H, Korfer A, Palmer PA, Evers P, de Riese W, KnuverHopf J (1990) Subcutaneous IL-2 and IFNα-2b in patients with metastatic renal cell carcinoma: the German experience. Mol Biother 2: 145
Kirkwood JM, Ernstoff MS (1991) Cutaneous melanoma: In: Biologic therapy of cancer. Lippincott, Philadelphia, p 311
Kreuser E-D, Wadler S, Thiel E (1992) Interactions between cytokines and cytotoxic drugs: putative molecular mechanisms in experimental hematology and oncology. Semin Oncol 19: 1
Kreuser E-D, Hilgenfeld RU, Matthias M, Hoksch B, Bower C, Oldenkott B (1992) A phase II trial of IFNα-2b with folinic acid and 5-FU administered by 4 hour infusion in metastatic colorectal cancer. Semin Oncol 19: 57
Krigel RL, Padavia-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL (1988) A phase I study of recombinant IL-2 plus recombinant β-interferon. Cancer Res 48: 3875
Kurzrock R, Talpaz M, Gutterman JU (1991) Interferons αβ,γ: basic principles and preclinical studies. In: Biologic therapy of cancer. Lippincott, Philadelphia, p 247
Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C (1989) Concomitant administration of recombinant human IL-2 and recombinant IFNα-2a in cancer patients: a phase I study. J Clin Oncol 7: 1726
Legha S, Plager Ring S (1992) A phase II study of biochemotherapy using IL-2 and IFNα-2a in combination with cisplatin, vinblastine, and DTIC in patients with metastatic melanoma. Proc Am Soc Clin Oncol 11: 343
Lienhard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ (1992) High dose recombinant TNFα in combination with IFNγ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52
Lindemann A, Hoffken K, Schmidt RE, Diehl V, Kloke O, Gamm H (1989) A phase II study of low dose cyclophosphamide and recombinant IL-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 28: 275
Lipton A, Harvey H, Givant E, Hopper K, Lawler J, Matthews Y, et al. (1993) II-2 and IFNα-2a outpatient therapy for metastatic renal cell carcinoma. J Immunother 13: 122
Lotze MT (1992) The treatment of patients with melanoma using interleukin 2, IL-4, and tumor infiltrating lymphocytes. Human Gene Ther 3: 167
Lotze MT, Rosenberg SA (1991) Interleukin 2: clinical applications: In: Biologic therapy of cancer. Lippincott, Philadelphia, p 159
Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko J (1992) Phase I trial of IL-2 plus γ-interferon. J Immunother 11: 50
Mavligit G, Zukwiski A, Wallace S (1990) Tumor regression after hepatic arterial infusion of recombinant TNF in patients with colon carcinoma metastatic to the liver. Proc Am Soc Clin Oncol 9: 118
McCune CS, Marquis DM (1990) IL-1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 50: 1212
Mitchell MS (1992) Chemotherapy in combination with biomodulation: a 5 year experience with cyclophosphamide and IL-2. Semin Oncol 19: 80
Mitchell MS, Kempf RA, Havel W (1988) Effectiveness and tolerability of low dose cyclophosphamide and low dose intravenous IL-2 in disseminated melanoma. J Clin Oncol 6: 409
Morgan DA, Ruscetti FW, Gallo RG (1976) Selective in vitro growth of T-lymphocytes from normal bone marrows. Science 193: 1007
Mulcher NH, Schrafford-Koops H, Sleijfer DT (1991) IFN and DTIC in the treatment of disseminated malignant melanoma. Proc Am Soc Clin Oncol 10: 1020
Mule JJ, Rosenberg SA (1991) Combination cytokine therapy: experimental and clinical trials: In: Biologic therapy of cancer. Lippincott, Philadelphia, p 393
Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA (1990) In vivo administration of recombinant IL-6 mediates tumor regression in mice. J Exp Med 17: 629
Negrier MS, Pourreau CN, Palmer PA, Panchere JY, Mercatello A, Viens P (1992) Phase I trial of recombinant IL-2 followed by recombinant TNF in patients with metastatic cancer. J Immunother 11: 93
Neidhart JA, Anderson SA, Harris JE (1991) Vinblastine fails to improve response of renal cancer to IFN-α n1: high response rate in patients with pulmonary metastasis. J Clin Oncol 9: 832
Orr D, Oldham R, Levis M, Bertoli L, Birch R (1989) Phase I study of the sequence administration of etoposide and recombinant TNF in patients with advanced malignancy. Proc Am Soc Clin Oncol 8: 741
Osaulo S, Jansen R, Naipal A (1989) In vivo effects of combination treatment with recombinant IFN-γ and α in metastatic melanoma. Int J Cancer 43: 1001
Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of TNF and IL-2 in the activation of human cytotoxic lymphocytes: effect of TNF and IL-2 in the generation of human LAK cell cytotoxicity. Cancer Res 48: 788
Paciucci PA, Bekesi JG, Ryder RS, Odchimar R, Chahinian PA, Holland JF (1991) Immunotherapy with IL-2 by constant infusion and weekly doxorubiein. Am J Clin Oncol 14: 341
Paolozzi F, Zamkoff K, Doyle M (1989) Phase I trial of recombinant IL-2 and recombinant β-IFN in refractory neoplastic diseases. J Biol Response Mod 8: 122
Raymonds J, Logan M, Ernstoff M (1990) Phase I study of TNF combined with mitomycin C in cancer patients. Proc Am Soc Clin Oncol 9: 286
Redman BG, Flaherty L, Chou T-H, Nakeff A, Pillote K, Kaplan J (1991) Sequential dacarbazine/cisplatin and IL-2 in metastatic melanoma: immunological effects of therapy. J Immunother 10: 147
Renal Cancer Study Group (1987) Phase II study of recombinant IFN.γ on renal cell carcinoma. Cancer 60: 929
Richards JM, Mehta N, Rammig K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment o,, metastatic melanoma. J Clin Oncol 10: 1338
Rinehart J, Makpeis L, Young D (1986) Phase I/II trial of human recombinant β-interferon serine in patients with renal cell carcinoma. Cancer Res 46: 5364
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin 2 in the treatment of 652 cancer patients. Ann Surg 210: 474
Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp CA, Calabro S (1989) Combination therapy with IL-2 and α-IFN for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863
Rubin JT, Lotze MT (1993) Adoptive cellular immunotherapy of cancer: In: Biologic approaches to cancer treatment. McGraw-Hill, New York, p 379
Schiller JH, Willson JK, Bittner G (1986) Antiproliferative effects of interferons on human melanoma cells in the human cololy-forming assay. J Interferon Res 6: 615
Schiller JH, Alberti DB, Arzoomanian RZ (1990) Phase I trial of combination of recombinant γ-IFN and recombinant TNFα. Proc Am Cancer Res 31: 183
Shiloni E, Poullart P, Janssens J, Splinter T, Di Peri T, Symann M, et al (1989) Sequential dacarbazine chemotherapy followed by recombinant IL-2 in metastatic melanoma: a pilot multicentre phase I/II study. Eur J Cancer 25: S45
Smith KA (1988) Interleukin 2: inception, impact, and implications. Science 240: 1169
Smith JW, Urba WJ, Clark JW, Longo DL, Farrell M, Creekmore SP, et al (1991) Phase I evaluation of recombinant TNF given in combination with recombinant IFN-γ. J Immunother 10: 355
Spagnoli GC, Juretic A, Schultz-Thater E, Dellabona P, Filgueria L, Horig H (1993) On the relative roles of IL-2 and IL-10 in the generation of LAK cell activity. Cell Immunol 146: 391
Spencer WF, Linehan WM, Walther MM, Haas GP, Lotze MT (1992) Immunotherapy with IL-2 and α-IFN in patients with metastatic renal cell carcinoma with in situ primary cancers: a pilot study. J Urol 147: 24
Spicer DV, Kelley A, Herman R, Dean G, Stevenson L, Mitchell MS (1992) Low dose recombinant IL-2 and low dose cyclophosphamide in metastatic breast cancer. Cancer Immunol Immunother 34: 424
Spriggs DR, Yates SW (1992) Cancer chemotherapy-experiences with TNF administration in humans: In: Tumor necrosis factors: the molecules and their emerging role in medicine. Raven Press, New York, p 383
Stahl M, Wilke H-J, Seeber S, Schmoll HJ (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 19: 70
Stotter H, Custer MC, Bolton ES, Gwedez L, Lotze MT (1991) IL-7 induces LAK cell activity and is regulated by IL-4. J Immunol 146: 150
Taylor C, Hersh E, Plezia P (1989) A phase I and pharmacokinetic study of recombinant TNF and doxorubicin. Proc Am Soc Clin Oncol 8: 183
Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzales R (1992) A SWOG phase I study of the sequential combination of recombinant IFN-γ and recombinant IL-2 in patients with cancer. J Immunother 11: 176
Valone FH, Gandura DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR (1991) IL-2, cisplatin, and 5-FU for patients with non-small cell lung and head/neck carcinomas. J Immunother 10: 207
Verdi CJ, Taylor CW, Croghan MK, Dalke P, Meyskens FL, Hersh EM (1992) Phase I study of low dose cyclophosphamide and recombinant IL-2 for the treatment of advanced cancer. J Immunother 11: 286
Viens P, Blaise D, Stoppa AM, Brandely M Baume D, Olive D (1992) IL-2 in association with increasing doses of IFN-γ in patients with advanced cancer. J Immunother 11: 218
Weber J, Rosenberg SA (1993) Phase I studies of the pharmacokinetics, toxicities, and biologic effects of IL-6 in patients with refractory advanced malignancies. J Immunother 13: 74
Whitehead RP, Figlin R, Citton ML, Pfile J, Moldauer N, Patel D (1993) A phase II trial of concomitant human IL-2 and IFNα-2a in patients with disseminated malignant melanoma. J Immunother 13: 117
Yang SC, Owen SL, Mendigurea RA, Grimm EA, Hong WK, Roth JA (1990) Combination immunotherapy for non-small cell lung cancer. Results with IL-2 and TNFα. J Thorac Cardiovasc Surg 99: 8
Yasumoto K, Miyazaki K, Nagashima A (1987) Induction of LAK cells by intrapleural instillations of recombinant IL-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 47: 2184
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heaton, K.M., Grimm, E.A. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother 37, 213–219 (1993). https://doi.org/10.1007/BF01518513
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01518513